Various multinational pharmaceutical companies have already shown interest in this company from Cordoba, located in the Cordoba Science and Technology Park “Rabanales 21”.

The company Canvax Biotech has announced the development of a cellular biosensor that is much more sensitive than others developed until this time by competing firms. This is a biological system that amplifies the signal emitted by a specimen one million times smaller than those required by other sensors until now, deciphering its composition.

Further, the biosensor can detect more than one substance at a time, whether this be a medicine, a chemical compound of another type or even microorganisms. This facilitates the detection and classification of bacteria in patients with infection, allowing medical personnel to choose an appropriate antibiotic treatment much more quickly and efficiently.

Other uses for the biosensor that are being studied by researchers from Canvax are the diagnosis of cancer in very early stages and the detection of allergens, the latter facilitating a personalized treatment for patients with diverse types of allergic reactions. All of these features have aroused the interest of various multinational pharmaceutical companies in the company from Cordoba.

Canvax Biotech, founded in 2001 with the support of the University of Cordoba and the Reina Sofía University Hospital, is part of the Instituto Sectorial de Empresas (Inssec). As of today the company has seven worldwide patents under the PCT, covering its different technological processes.